• Home
  • Grifols International, S.A.

Grifols International, S.A.

About Grifols International, S.A.

Grifols Partnership is a contract development and manufacturing platform (CDMO) focused on added value injectable products, with a large, international experience in the development and manufacturing of many types of sterile drug products. We specialize in small molecule intravenous solutions and offer high quality pharmaceutical development and product manufacturing. 

We are able to leverage the resources and experiences of the larger Grifols organization to provide significant value to our partners. 

Technological Capabilities:

  • Drug Product Development
  • Small Molecule Drug Products
  • Terminal Sterilization
  • Light and Oxygen  sensitive products
  • Vials (2,5 to 50 mL)
  • Glass Bottles (50 to 500 mL)
  • Flexible Containers (PP bags, 50 to 1000 mL)
  • Diluents
  • FFS technology for PP bags
  • Regulatory Approvals
Grifols, with more than 25,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous inn...

Read more Show less
Certifications
  • CE
  • FDA
    FDA
  • GMP
  • ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • ES
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
Contract Service
Primary activities
Contract Manufacturer
Contact info
Show contact info Hide contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Frankfurt, Germany
1-3 November 2022
View Exhibitor Profile

Products from Grifols International, S.A. (4)

  • Pre-mixed IV solutions: bags

    Product Pre-mixed IV solutions: bags

    Premixed solutions in customized IV bags, sizes: 50, 100, 250, 500 and 1000 ml (one port, two ports, twist-off, luer valve)Grifols Partnership is specialized in developing and manufacturing high quality sterile solutions in a wide range of containers made from a variety of materials in different sizes to...
  • Pre-mixed IV solutions: vials and bottles

    Product Pre-mixed IV solutions: vials and bottles

    Glass vials (5ml-50ml)Glass bottles (50ml-500ml)Grifols Partnership is specialized in developing and manufacturing high quality sterile solutions in a wide range of containers made from a variety of materials in different sizes to suit every need in both the human and veterinary markets. Grifols Partnership o...
  • Water for Injection

    Product Water for Injection

    Because diluent is as important as your API, Grifols offers you Water for Injection Drug Master File (DMF)
  • 0,9% Sodium Chloride Injection USP

    Product 0,9% Sodium Chloride Injection USP

    Sodium Chloride 0,9% USPAvailable in flexible container 50mL, 100mL, 250mL, 500mL, 1000mL

Grifols International, S.A. Resources (10)

  • Grifols Partnership - Parenterals CDMO - Flyer

    Brochure Grifols Partnership - Parenterals CDMO - Flyer

    Grifols Partnership is a contract development and manufacturing platform (CDMO) focused on added value injectable products, with a large, international experience in the development and manufacturing of many types of sterile drug products. We specialize in small molecule intravenous solutions and offer high quality pharmaceutical development and product manufacturing. Our portfolio also includes products which require careful design and assembly, including medical devices and bags for blood storage and collection.
  • Grifols Partnership - Parenterals CDMO

    Brochure Grifols Partnership - Parenterals CDMO

    Brochure describing Grifols Partnership services, products and capabilities offered to pharmaceutical companies. Featuring two FDA approved Manufacturing sites
  • Grifols Partnership - Vial filling

    Brochure Grifols Partnership - Vial filling

    Grifols Partnership: your CMO for filling vials. Because diluent is as important as your API
  • Rare specialist for tomorrow's medicines

    Brochure Rare specialist for tomorrow's medicines

    Rare specialist for tomorrow's medicines
  • Supporting Small and emerging pharma through collaboration and specialized expertise

    Whitepaper Supporting Small and emerging pharma through collaboration and specialized expertise

    Growth in the pharmaceutical industry is no longer exclusively driven by large pharmaceutical companies. The switch in the marketplace from a focus on blockbuster drugs to an emphasis on therapies that treat orphan and rare diseases has led to the rise of small and emerging pharma companies founded to advance novel medicines for specialized patient populations. These innovators require the support of contract service providers that recognize their unique requirements.
  • Catering to a growing demand for Small-volume parenteral manufacturing

    Whitepaper Catering to a growing demand for Small-volume parenteral manufacturing

    Drug candidates are becoming increasingly complex as manufacturers continue to focus on niche and personalized medicines. Contract development and manufacturing organizations with process and capacity, flexibility, and wide-ranging expertise in small-volume GMP manufacturing are needed to support efforts by pharma companies to rapidly bring these specialized products to the market.
  • Trends shaping the dynamic market for parenterals

    Whitepaper Trends shaping the dynamic market for parenterals

    Demand for parenteral drugs continues to increase as the overall drug market expands and new therapies for both chronic and rare diseases enter the pipeline. Manufacturers are faced with increasing complexity, not only because of the drug substances, but also due to formulations, patient-centric delivery technologies,and regulatory requirements, which are all further complicated by abbreviated development timelines.
  • The critical role of continous improvement in parenteral drug manufacturing

    Whitepaper The critical role of continous improvement in parenteral drug manufacturing

    In the competitive pharmaceutical manufacturing landscape, the ability to continuously achieve improvements in efficiency and productivity is essential to success. Given the higher complexity of parenteral drug manufacturing, continuously improving production processes is also paramount for ensuring the highest level of quality.
  • Investing in Form-Fill-Seal technology

    Whitepaper Investing in Form-Fill-Seal technology

    Extensive process understanding is required to ensure the consistent manufacture of high-quality sterile parenteral products. At Grifols, our use of state-of-the-art automated aseptic processing systems, including form-fill-seal (FFS) technology, ensures control with minimal human intervention.
  • Grifols Partnership - Company presentation

    Video Grifols Partnership - Company presentation

    Grifols Partnership is a business to business contract development and manufacturing platform for sterile solutions (small molecules) and lipid emulsions with over 75 years of experience in producing high-quality intravenous solutions for the pharmaceutical industry worldwide.

    Wach our video and learn more about our services.